lodapolimab

{
  "id": "MLC-T-ONC-014875",
  "term": "lodapolimab",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, lodapolimab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.",
  "synonyms": [
    "anti-PD-L1 checkpoint antibody LY3300054",
    "anti-PD-L1 monoclonal antibody LY3300054",
    "anti-programmed cell death ligand 1 checkpoint antibody LY3300054",
    "WHO 11185"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lodapolimab/"
}